The Clinical Trials Office (CTO) provides administrative and educational support for clinical, translational and population based studies for investigators of the NYU Cancer Institute (NYUCI). It also provides the research staff to carry out the objectives of the study. It serves as the main coordinating center for protocol development, regulatory and compliance guidance, administrative submissions, data collection and management, data analysis, and quality assurance. It also serves as the administrative interface to other clinical research organizations at the NYU Langone Medical Center (NYULMC). The goals of this resource are to: facilitate clinical trials by providing a framework for trial development, submission for institutional approval (PRMS and IRB), budgeting and conduct of clinical trials;ensure appropriate standards of clinical trial conduct across the institution and strategic alliances by maintaining data management, regulatory, and nursing guidelines as well as auditing conduct of trials;provide educational programs and mentorship for the CTO staff, fellows, and clinical investigators;and promote interdisciplinary collaboration and venues for translating research findings to the clinical arena. Since the last review, a new medical director was appointed and a number of senior level positions were established and subsequently filled. This resulted in streamlining processes and the development of new metrics to better assess resource allocations. Since the last review accruals increased at the main institution and at Bellevue Hospital Center. Currently, the CTO supervises 49 research staff and manages 151 open protocols. The CTO continues to expand and improve its function to serve as the central coordinating center for the clinical research enterprise at the NYUCI.
;The CTO works as a centralized coordinating center for all aspects of conducting clinical research at NYUCI. The structure provided by the CTO assists to move novel therapeutic agents from bench to bedside and provide an avenue for access to clinical trials all patient populations.
|Jin, Honglei; Yu, Yonghui; Hu, Young et al. (2015) Divergent behaviors and underlying mechanisms of cell migration and invasion in non-metastatic T24 and its metastatic derivative T24T bladder cancer cell lines. Oncotarget 6:522-36|
|Zhou, Sherry; Weitzman, Michael; Vilcassim, Ruzmyn et al. (2015) Air quality in New York City hookah bars. Tob Control 24:e193-8|
|Brocato, Jason; Costa, Max (2015) 10th NTES Conference: Nickel and arsenic compounds alter the epigenome of peripheral blood mononuclear cells. J Trace Elem Med Biol 31:209-13|
|Cohen, Mitchell D; Vaughan, Joshua M; Garrett, Brittany et al. (2015) Acute high-level exposure to WTC particles alters expression of genes associated with oxidative stress and immune function in the lung. J Immunotoxicol 12:140-53|
|Ota, Mitsuhiko; Horiguchi, Masahito; Fang, Victoria et al. (2014) Genetic suppression of inflammation blocks the tumor-promoting effects of TGF-? in gastric tissue. Cancer Res 74:2642-51|
|McKinney, Caleb; Zavadil, Jiri; Bianco, Christopher et al. (2014) Global reprogramming of the cellular translational landscape facilitates cytomegalovirus replication. Cell Rep 6:9-17|
|Vazquez-Cintron, Edwin J; Vakulenko, Maksim; Band, Philip A et al. (2014) Atoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasm. PLoS One 9:e85517|
|Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana et al. (2014) A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer 14:154-60|
|Wu, Meng; Yang, Feikun; Ren, Zhihua et al. (2014) Identification of the nuclear localization signal of SALL4B, a stem cell transcription factor. Cell Cycle 13:1456-62|
|Kaneko, Syuzo; Bonasio, Roberto; Saldaña-Meyer, Ricardo et al. (2014) Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. Mol Cell 53:290-300|
Showing the most recent 10 out of 491 publications